Abstract

The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved the prediction of survival and early mortality compared with the prognostic value of static frailty level at baseline.

Subjects:
Clinical Trials and Observations, Lymphoid Neoplasia, Multiple Myeloma
1.
Palumbo
A
,
Bringhen
S
,
Mateos
MV
, et al.
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
.
Blood
.
2015
;
125
(
13
):
2068
-
2074
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Mian
H
,
McCurdy
A
,
Giri
S
, et al.
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review
.
Blood Cancer J
.
2023
;
13
(
1
):
6
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Moore
K
,
Turesson
I
,
Genell
A
, et al.
Improved survival in myeloma patients–a nationwide registry study of 4,647 patients >75 years treated in Denmark and Sweden
.
Haematologica
.
2023
;
108
(
6
):
1640
-
1651
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Mian
H
,
Wildes
TM
,
Vij
R
,
Pianko
MJ
,
Major
A
,
Fiala
MA
.
Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study
.
Blood Cancer J
.
2023
;
13
(
1
):
76
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Yao
Y
,
Sui
WW
,
Liao
AJ
, et al.
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study
.
Age Ageing
.
2022
;
51
(
1
):
afab211
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Scheubeck
S
,
Ihorst
G
,
Schoeller
K
, et al.
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
.
Cancer
.
2021
;
127
(
18
):
3422
-
3436
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Stege
CAM
,
Nasserinejad
K
,
Van der Spek
E
, et al.
Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study
.
J Clin Oncol
.
2021
;
39
(
25
):
2758
-
2767
.
Google Scholar
Crossref
Search ADS
 
8.
Groen
K
,
Stege
CAM
,
Nasserinejad
K
, et al.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
.
eClinicalMedicine
.
2023
;
63
:
102167
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Rizopoulos
D
.
Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data
.
Biometrics
.
2011
;
67
(
3
):
819
-
829
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
Zweegman
S
,
Levin
MD
,
Klein
SK
, et al.
Feasibility and efficacy of dose adjusted melphalan-prednisone-bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed multiple myeloma; the non-randomised phase II HOVON 123 study [abstract]
.
Blood
.
2016
;
128
(
22
):
3305
.
Google Scholar
Crossref
Search ADS
 
11.
Coulson
AB
,
Royle
K-L
,
Pawlyn
C
, et al.
Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss (UK-MRA Myeloma XIV trial)): a study protocol for a randomised phase III trial
.
BMJ Open
.
2022
;
12
(
6
):
e056147
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Cook
G
,
Pawlyn
C
,
Royle
KL
, et al.
Dynamic frailty assessment in transplant non-eligible newly diagnosed myeloma patients: initial data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): a frailty-adjusted therapy study [abstract]
.
Blood
.
2023
;
142
(
suppl 1
):
4748
.
Google Scholar
 
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
Sign in via your Institution